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Summary Tamoxifen is an effective agent preventing mammary carcinogenesis in rats but causing liver tumours. Idoxifene is a more potent
antioestrogen and is effective in patients with advanced breast cancer. We therefore compared the effects of idoxifene with tamoxifen on
mammary carcinogenesis and hepatic DNA adduct formation. To do this, we undertook a study designed to compare tamoxifen with idoxifene
as a chemopreventive agent in rats inoculated with Mmethyinitrosourea (MNU) and also measured hepatic adduct formation. We examined
the time to mammary tumour development in 272 female Ludwig/Wistar/Olac rats treated with MNU followed by tamoxifen (5 mg kg-'),
equimolar idoxifene orvehicle three times a weekfor up to 24 weeks. To determine duration of effect, a second study was carried out whereby
all of the 129 animals surviving at the end of treatment were entered into a surveillance programme for 27 weeks after the end of the
administration period. Hepatic DNA adduct formation was examined by 32P-postlabelling in a group of rats after 24 weeks' treatment. In the
first study, both idoxifene and tamoxifen were effective in preventing tumour growth as only 2 out of 21 (10%) MNU and vehicle-treated
animals were alive and tumour free after 24 weeks compared with 13 out of 22 (59%) animals receiving MNU followed by idoxifene or
tamoxifen (P < 0.001). The second study showed that, in both idoxifene- and tamoxifen-treated animals, a progressive regrowth of tumours
occurred after cessation of therapy, as by the end of the observation period only four idoxifene-treated animals and one tamoxifen-treated
animal were free from disease. In the subset of animals tested, tamoxifen-treated animals had approximately 100 times higher levels of DNA
hepatic adducts than idoxifene-treated animals. Adducts were not seen in the control group. These results indicate that idoxifene is as
effective a chemopreventive agent as tamoxifen in the rat while causing only very low levels of DNA adducts in liver tissue and suggest that
idoxifene may be a well-tolerated chemopreventive agent in women who are at increased risk of breast cancer.
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Tamoxifen, currently used in the treatment ofpatients with breast
cancer, has been shown to reduce the incidence of contralateral
breast cancer in women who have been treated for primary breast
cancer (EBCTCG, 1992). These results provided the impetus for
the use of tamoxifen to attempt to prevent the development of
breast cancer in women who are at high risk (Powles et al, 1989).
However, tamoxifen is associated with uterine carcinogenesis and
there are an estimated one or two cases of uterine carcinoma
annually per 1000 women treated (Seoud et al, 1993). Although
not known to cause liver tumours in humans, there is evidence that
tamoxifen is a hepatic carcinogen in rats, possibly related to the
metabolism of tamoxifen to cx-hydroxytamoxifen, a metabolite
with high DNA-binding activity (Phillips et al, 1994a, b). This
metabolite is also found in breast cancer patients receiving tamox-
ifen (Poon et al, 1995). For these reasons, much work has been
done to develop novel antioestrogens. These include LY117018
(Scholl et al, 1983), droloxifene (Bruning, 1992), toremifene
(Vogel et al, 1993) and ICI 182, 780 (Wakeling, 1991), the last one
showing properties of a pure antioestrogen. Some of these
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compounds would be unsuitable as preventive agents. Thus, apure
antioestrogen such as ICI 182, 780 might cause osteoporosis, and
LY 117018 is rapidly conjugated and excreted (Scholl et al, 1983).
However, both toremifene and droloxifene mightbe suitable. Each
causes little or no DNA formation in the liver, in contrast to
tamoxifen, when administered to rats (White et al, 1992), which
could imply a potentially better safety profile for these newer
analogues. Recently, we have developed another antioestrogen
structurally related to tamoxifen, named idoxifene, and have
reported its evaluation in a phase I clinical trial (Coombes et al,
1995). This compound has lower oestrogenic but greater anti-
oestrogenic activity than tamoxifen (Chander et al, 1991).
In addition, iodination ofthe molecule at the 4-position, as well
as reducing oestrogenic activity, also blocks 4-hydroxylation and
hence subsequent inactivation by glucuronidation (McCague et al,
1990). Idoxifene shows a 2.5- to 5-fold higher affinity for the
oestrogen receptor (ER) compared with tamoxifen and was 1.5-
fold more effective in inhibiting oestrogen-induced growth of
MCF-7 cells (McCague et al, 1990; Chander et al, 1991). In rats
bearing N-methylnitrosourea (MNU)-induced mammary tumours,
idoxifene was more effective in causing tumour regression
(Chander et al, 1991). Rat hepatocytes metabolize idoxifene 2.5
times more slowly than tamoxifen and rats have a doubling ofthe
terminal half-life of idoxifene compared with tamoxifen (Haynes
et al, 1991). Preclinical toxicology of idoxifene was carried out
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and this showed, in a single-dose study in mice at 100 mg kg-', no
mortality orbehaviourial change. Histology showed mild vacuola-
tion of the interstitial cells in the ovary and mild dilatation of the
uterine glands but no other abnormality. A repeat-dose study ofup
to 50 mg kg-1 per dose for 4 weeks showed mild reduction in
weight, reduced uterine and ovarian weight, and ovarian intersti-
tial hyperplasia. No other abnormality was seen (Coombes et al,
1995). For all these reasons, we felt that idoxifene might be a
candidate for a chemoprevention agent forbreast cancer. To assess
the potential ofidoxifene we carried out a series of studies in rats,
in which mammary tumour formation had been initiated by MNU,
to compare its effects with those oftamoxifen in this system.
MATERIALS AND METHODS
Design of chemoprevention studies
An initial study was carried out in order to determine the magni-
tude of the effect of idoxifene in rats in which mammary tumour
induction had been initiated by MNU. In this study, 143 rats were
randomized to receive idoxifene, tamoxifen or vehicle alone and
tumour size was monitored over various periods of time. One
batch consisted of 38 animals that were treated for 12 weeks and
then killed; a second consisted of40 animals that were treated for
18 weeks before killing and a third consisted of 65 animals and
these were killed at 24 weeks.
We then carried out a second study with 129 animals with
prolonged follow-up beyond the end of treatment (batch 4).
Animals were treated for 24 weeks and those surviving were
followed up for a further 27 weeks before the animals that were
still alive were killed.
Animals
In-bred virgin female (Ludwig/Wistar/Olac) rats that had been
treated with MNU were supplied by Olac, Oxon, UK. The model
used was as described previously (Chander et al, 1991). Briefly,
45- to 55-day-old rats were induced with three inoculations of
0.5 ml of MNU (50 mg kg-1 body weight) via the tail vein over a
period of 6 weeks. Tumours were expected to occur 12-16 weeks
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Figure 1 The graph shows the time to tumour development to 2 10 mm in
all animals treated with vehicle (-- - -), idoxifene -and tamoxifen ......
afterthefirst inoculation. In this study 272 adultvirgin female rats,
each weighing about 200 g, commenced treatment 7 weeks after
the first inoculation with MNU. Each batch of rats was randomly
allocated into three groups fortreatment with idoxifene, tamoxifen
or vehicle respectively. Charing Cross and Westminster Medical
School's institutional guidelines for animal welfare were followed
in these experiments.
Drug administration and tumour measurement
Idoxifene was synthesized as described previously (McCague et
al, 1989) and tamoxifen was a gift from Dr A Wakeling (Zeneca,
UK). Idoxifene and tamoxifen were dissolved in peanut oil.
Dosages were at concentrations equimolar to 5 mg of tamoxifen
per kg rat body weight at each injection. Drugs (or vehicle) were
administered subcutaneously 3 days per week for 12-24 weeks in
batches 1-5 (see below). All rats were weighed at the start of the
experiment and once every 3 weeks thereafter. Tumours were
Table 1 Chemoprevention by tamoxifen and idoxifene: tumour incidence in study 1
Batch 1 Batch 2 Batch 3
Alive + tumour Alive + tumour Alive + tumour
tumour free .10 mm Dead tumour free .10 mm Dead tumour free .10 mm Dead
12 weeks
Idoxifene 13 2 0 8 2 1 20 1 1
Tamoxifen 8 3 0 11 1 2 21 0 1
Control 5a 6 1 10 5 0 8 12 1
18 weeks
Idoxifene - - - 8 0 3 14 6 2
Tamoxifen - - - 8 4 2 16 5 1
Control - - - 4 10 1 5 12 4
24 weeks
Idoxifene - - - - - - 13 3 5+1b
Tamoxifen - - - - - - 13 5 3+1b
Control - - - - - - 2 11 8
aNumber includes one animal that had a tumour.10 mm at 9 weeks but that had disappeared at 12 weeks. bOne rat in each group was culled because of
haemorrhage but there was no evidence of tumour 2 5 mm.
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Table 2 Chemoprevention by tamoxifen and idoxifene: tumour incidence
during treatment and on follow-up (study 2)
Time Treatment Alive and Tumour Dead
tumour free .10 mm
12 weeks Idoxifene 31 8 5
Tamoxifen 37 6 0+1*
Control 24d 14 3
18 weeks Idoxifene 25 10 9
Tamoxifen 28a 14 1 + 1*
Control 11b 26 4
24 weeks Idoxifene 21 8 15
Tamoxifen 24 16 3+ 1*
Control 6c 24 11
36 weeks Idoxifene 8 14 22
Tamoxifen 18a 11 14 + 1
Control 2a 10 29
42 weeks Idoxifene 6 13 25
Tamoxifen 12a 13 18 + 1*
Control 1 4 36
51 weeks Idoxifene 4 7 33+
Tamoxifen 1 11 29 + 18 +2**
Control 1 1 39
aOne, 'two, cthree and dfour animals with tumour.10 mm at a previous time
point but now regressed. ++One animal culled because of haemorrhage at
week 45 - no previous tumour 2 10 mm; *One animal culled at 2 weeks
because of cerebral oedema. No tumour .5 mm; **Two animals culled
because of haemorrhage but no tumour .5 mm (weeks 47 and 48).
measured in two diameters. In batches 4 and 5, after the twenty-
fourth week had elapsed, dosing was stopped but weight and
tumour measurements continued every 3 weeks for a further 27
weeks. Rats were culled at the onset oftumour ulceration or if any
tumourdiameter exceeded 30 mm, or at the end ofthe study. Upon
death of an animal, the liver and tumours were removed, snap-
frozen and stored at-70°C for later analysis. Rats were also exam-
ined at post-mortem for evidence oftumour formation elsewhere.
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Measurement of adduct formation
DNA was isolated from homogenized rat liver using the
phenol-chloroform extraction method described previously
(Gupta, 1984). 32P-postlabelling analysis, using the nuclease P,
digestion method of sensitivity enhancement, was carried out as
described previously (White et al, 1992), except that apyrase was
not used to terminate the labelling reaction. Labelled adducts were
resolved by multidirectional thin-layer chromatography (TLC) on
polyethyleneimine-cellulose sheets (White et al, 1992), for which
the following solvents were used: Dl, 2.3 M sodium phosphate,
pH 5.8; D2, 2.28 M lithium formate, 5.52M urea, pH 3.5; D3,
0.52 M lithium chloride, 0.32 M Tris-hydrochloric acid, 5.52 M
urea, pH 8. D4 was omitted from the procedure. Each sample was
analysed twice and the average level of adducts calculated. The
reproducibility ofthe assay was ± 15%.
Statistical analysis
Kaplan-Meier survival curves and the log-rank test were used to
compare tumour occurrence between groups. As small tumours
often regress spontaneously, only those tumours 10 mm in diam-
eterorgreater were considered in the analysis oftumourincidence.
Occurrence oflarge tumours (.15 mm) was used as a surrogate for
survival. Animals that died without evidence of tumour were
censored at the time of culling without scoring an event in the
analyses. The batches of animals (1-3) that were killed early,
therefore, contributed only to the relevant part of the
Kaplan-Meier curve and were censored (if no tumour had already
occurred) at the time ofkilling (weeks 12-24).
RESULTS
Prevention of tumour growth and duration of effect
Overall, at 24 weeks the abilities of tamoxifen and idoxifene to
prevent tumorigenesis appear similarly effective when compared
with controls (Figure 1, P < 0.001).
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Idoxifene vs Control: log-rank test=15.54 d.f.=1 P<0.001
Tamoxifen vs Control: log-rank test=26.66 d.f.=1 P<0.001
Idoxifene vs Tamoxifen: log-rank test=0.71 d.f.=1 P=0.40
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Idoxifene vs Tamoxifen: log-rank test=0.17d.f.=1 P=0.68
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Figure 2 The graph shows the time to tumour development in batch 4 over the first 24 weeks treatment (A) and the time taken to develop tumours 2 10 mm by
randomization in batch 4: Symbols as Figure 1
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Table 1 shows the status oftreated animals at the different time
points. Thus, at 12 weeks, only 23 out of 48 (48%) of control
animals were alive and tumour free, whereas 41 out of 48 (85%)
and 40 out of 47 (85%) of the idoxifene- and tamoxifen-treated
animals respectively, were alive and tumour free at this stage. At
18 weeks, 22 out of 33 (67%) (idoxifene) and 24 out of 36 (67%)
(tamoxifen) were tumour free compared with only 9 out of 36
(25%) control animals. At 24 weeks, idoxifene- and tamoxifen-
treated groups had equal numbers ofanimals that were tumourfree
(13 out of 22) (59%). In contrast, only 2 out of 21 (10%) vehicle-
treated animals were still tumour free at 24 weeks.
The second study (Table 2) confirmed that both idoxifene and
tamoxifen provide substantial protection from tumorigenesis with
21 out of 44 (48%) and 24 out of 44 (55%) animals remaining
tumour free at 24 weeks respectively, compared with only 6 out of
41 (15%) control animals. When data from batches 1-4 are
combined, results for idoxifene and tamoxifen are similar at 12, 18
and 24 weeks with 85%, 67% and 59% of animals alive and
tumour free at each of these time points. At 36 and 42 weeks, a
greater number of idoxifene-treated animals had died but this is
not statistically significant. Animals died fromprogressive tumour
growth with very few exceptions (see footnote to Table 2).
To determine the duration of this effect after withdrawal of
treatment, we examined the development of tumours in each
group, subdividing the analysis into the first 24 weeks (on treat-
ment) and the subsequent 27 weeks (post treatment) (Figure 2A,
B). Figure 2A shows the tumour development on treatment for
batch 4. Figure 2B includes only those animals that were tumour
free (i.e. no tumour > 10 mm) at the end of treatment and shows
the post-treatment development oftumours. The data indicate that
during the post-treatment period there is progressive tumour
development in both tamoxifen- and idoxifene-treated animals.
At the end of the 27-week observation period, only four idox-
ifene-treated animals and one tamoxifen-treated animal were alive
and free from disease; similarly one control animal showed no
evidence oftumour at this time.
If we consider the time taken to develop large tumours (more
than 15 mm diameter) only, and using all available data, a similar
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proportion (54%) of idoxifene-treated animals developed large
tumours compared with tamoxifen-treated animals, and there was
a suggestion that the time taken to develop these tumours may be
longer for tamoxifen than idoxifene-treated animals (Figure 3).
Adduct formation in livers of treated and control
animals
No tumours, other than mammary tumours, were observed during
the study, but we compared the effects oftamoxifen, idoxifene and
vehicle on adduct formation in liver tissues of treated animals.
Fifteen livers (five from each treatment group) were obtainedfrom
animals culled after the 24-week treatment period. No adducts
were detected in the control liver DNA (Figure 4). Two ofthe five
idoxifene-treated animals showed no evidence ofadductformation
but three showed a very low adduct level, with achromatographic
mobility similar to that ofthe major tamoxifen adduct. The values
for the five idoxifene samples (mean of two determinations,
expressed as adducts per 108 nucleotides) were calculated to be 0,
0, 11.0, 8.4 and 10.2.
In contrast to these two groups, adducts were detected in all
tamoxifen-treated animals. The levels (expressed as adducts per
108 nucleotides) were 596, 1059, 644, 533 and 708. The adduct
profiles were typical of tamoxifen adducts in liver and in vitro
(Phillips et al, 1994 a, b) (Figure 4).
DISCUSSION
Ourresults show that idoxifene is similar to tamoxifen in its ability
to suppress tumorigenesis in rats treated with MNU. Essentially,
both drugs suppressed tumour formation during the period of
administration: when treatment was withdrawn the tumour inci-
dence gradually rose to control levels. Thus, at the end of the 27-
week observation period, nearly all animals hadpalpable tumours.
In the presence of large tumours (2 15 mm) it was obligatory to
cull animals if the tumour burden became too great. This, there-
fore, precludes a reliable analysis of survival. The nearest surro-
gate is the time to occurrence of a tumour of 2 15 mm. This
analysis suggests that tamoxifen may be superior to idoxifene in
this regard, but the difference failed to achieve statistical signifi-
cance. These results confirm several other groups' results demon-
strating the preventative effect of tamoxifen on tumour growth
(Jordan, 1993) but are the first to show that idoxifene has a similar
effect. The study also demonstrates that a potential benefit ofidox-
ifene compared with tamoxifen is its substantially lower ability to
form hepatic DNA adducts in rats in vivo, indicating that liver
Idoxifene vs Control: log-rank test=10.25 d.f.=1 P=0.001
Tamoxifen vs Control: log-rank test=28.25 d.f.=1 P<0.001
Idoxifene vs Tamoxifen: log-rank test=3.46 d.f.=1 P=0.06
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Figure 3 The graph shows the time taken to develop tumours of 2 15 mm
during the first 24 weeks in rats on treatment. Symbols as Figure 1
Figure 4 32P-postlabelling analysis of DNA isolated from rat liver. DNA was
digested, 32P-labelled and chromatographed on PEI-cellulose tic plates. (A)
DNA from a solvent-treated rat. (B) DNA from an idoxifene-treated rat (three
out of five samples displayed the adduct spot shown; the remaining two did
not). (C) DNA from a tamoxifen-treated rat
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tumorigenesis is unlikely to be a long-term side effect in a preven-
tion strategy.
The reason for the reduced adduct formation observed with
idoxifene is still not clear. However, there is a major interspecies
difference in idoxifene metabolism between rats and humans with
the 4'-hydroxy derivative of idoxifene being the major metabolite
in rats in vitro and in vivo (Vogel et al, 1993). This metabolite is so
far undetected in human plasma (Coombes et al, 1995). There is a
similar situation with tamoxifen in which 4-hydroxylation is a
major metabolite in rodents but only a minor circulating metabo-
lite in humans (unpublished results). However, the a-hydroxylated
compound seems to be the major compound responsible for
hepatic carcinogenesis of tamoxifen in rats (Phillips et al, 1994a,
b) and differences in the extent of its formation may go some way
to explaining the observed differences in hepatic adduct formation
between the two species. Although idoxifene is also ax-hydroxyl-
ated by rat hepatocytes (Haynes et al, 1991) it forms DNA adducts
at levels two orders of magnitude lower than those formed by
tamoxifen. It has been suggested (Potter et al, 1994) that both at-
hydroxylation and 4-hydroxylation may be needed for maximal
adduct formation. Moreover, the activation mechanism proposed
would not operate for a 4'-hydroxy derivative. Hence, idoxifene
may be an intrinsically safer alternative to tamoxifen in the
preventative setting.
Our previous study (Coombes et al, 1995) has shown that, in
humans, there are other important quantitative differences between
tamoxifen and idoxifene in that the latter has an approximately
three-fold longer terminal half-life. Idoxifene also has a 50%
lower clearance rate than tamoxifen.
A further important feature of idoxifene, previously demon-
strated by our group (Chander et al, 1991), is its reduced
uterotrophic activity in rats. In this earlier study we demonstrated
that, after 21 days treatment, the uterine weight was significantly
reduced when compared with tamoxifen (P = 0.006). Despite this,
10 mg kg-' idoxifene was capable of inhibiting the oestradiol-
induced uterotrophic effect. Further, when analysed in a vaginal
cornification assay, idoxifene failed to reveal any oestrogenic
activity. Again, idoxifene was able, unlike tamoxifen, to
completely block oestradiol-induced comification. Thus, although
the current study did not specifically address the issue of
idoxifene-induced uterine neoplasia, it seems probable that such
effects will be less than with tamoxifen.
Other potential side-effects of tamoxifen in chemoprevention
have been summarized (Powles et al, 1989) and the placebo-
controlled preventative study has been reported previously
(Powles et al, 1990). The majority of subjective side-effects
reported in the phase I study of idoxifene by our group seem very
similar to those of tamoxifen (Coombes et al, 1995) although
further, longer term assessment in patients is required to assess
effects on plasma lipids, bone density and the retina.
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